IFNA2 and cryohydrocytosis: For the past decade, therapy with pegylated interferon-α (Peg-IFN-α) and ribavirin (RBV) yielded sustained virological response (SVR) rates of 40–50% among treatment naïve CHC patients with HCV genotype 1 infection [5, 6].